The NCI Development Therapeutics Program (DTP) provides services and resources to the academic and private-sector research communities worldwide to facilitate the discovery and development of new cancer therapeutic agents. Since its inception in 1955 by Congress, DTP has supported the development of more than 40 US-licensed anti-cancer agents through extensive collaborations with academic, pharmaceutical and biotechnology industries, including Paclitaxel, Romidepsin, Eribulin, Sipuleucel-T, and Dinutuximab (Ch14.18).
Today, most of DTP’s drug discovery and development services are available for academic and private researchers through applying for NCI Experimental Therapeutic program (NExT). Under this new framework, DTP continues to help academic and private sectors to overcome financial and technical barriers, particularly through supporting high-risk treatments for rare cancers, and facilitate the movement of promising therapeutic agents from scientists’ bench side to patients’ bed side.
DTP drug discovery and pre-clinic development services
Discovery services (NCI60 screening etc.) and pre-clinical support (pharmacology, toxicology and cGMP production etc.).
Synthetic compounds, natural products, biological samples and standards.
DTP databases and searching/analysis tools
Bulk DTP chemical and biological data for searching and download, COMPARE analysis.
DTP grant programs
Grants for preclinical anti-cancer drug discovery and treatment, including small molecules, natural products and biological agents.
Jerry M. Collins, Ph.D., is an internation-
nized pharmacologist. He has been closely associated with NCI’s drug development efforts for more than 25 years, first as an NCI intramural investigator and then as the Chief of the Pharmacokinetics Section. More…